ACE Kinetics Healthcare

AceKinetics is a preclinical-stage biotechnology company focused on developing next-generation recombinant human ACE2 (rhACE2) therapies for inflammatory and fibrotic diseases. A spin-off from the University of Florida, the company utilizes a proprietary platform to engineer long-acting versions of the ACE2 protein, overcoming the pharmacokinetic limitations of earlier rhACE2 candidates. Its primary therapeutic focus includes pulmonary arterial hypertension (PAH), acute respiratory distress syndrome (ARDS), and chronic kidney disease (CKD). Additionally, AceKinetics has explored the use of its rhACE2 platform as a decoy receptor to treat COVID-19 by neutralizing the SARS-CoV-2 virus and mitigating systemic inflammation. The company's approach aims to restore balance to the renin-angiotensin system (RAS) to treat a wide range of cardiovascular and pulmonary conditions.